Antriabio Inc., of Louisville, Colo., said it closed a $13 million financing as part of a planned private placement transaction. Under the terms, accredited investors paid $1 per share. The amount raised to date includes investments made by two South Korean-based pharmaceutical companies, Aju Pharm Co. Ltd. and Ildong Pharmaceutical Co. Ltd., as well as a South Korean-based investment fund, Medici Investment Co. Ltd. The company will use the proceeds for general corporate purposes, including the phase I study of AB-101, an injectable once-weekly basal insulin, as well as emerging pipeline candidates for patients with type 1 and type 2 diabetes. Antriabio's recently filed IND for AB-101 became effective without hold on July 1, and dosing of the first patient is expected prior to the end of this month.

Cohbar Inc., of Menlo Park, Calif., closed a previously announced nonbrokered private placement offering after issuing about 3.4 million units at a price of $1.50 each for total proceeds of about $5.16 million. Each unit consists of one share of the company's common stock and one common stock purchase warrant. The company intends to use the proceeds primarily to continue advancing its lead mitochondria-based therapy candidate into clinical studies targeted for early 2018, and for general corporate purposes.

Strongbridge Biopharma plc, of Dublin, entered a $50 million senior credit facility with CRG LP to retire its existing debt facility and provide additional capital for the company. It initially borrowed $40 million and has the option to borrow $10 million more based upon the achievement of certain revenue milestones on or prior to June 30, 2018. The agreement has a six-year term with three years of interest-only payment. CRG purchased $3 million of Strongbridge ordinary shares (NASDAQ:SBBP) at a price of $6.98 per share.

Targovax ASA, of Oslo, Norway, said it had allocated 323,268 shares (Oslo:TRVK) to subscribers in its subsequent offering, which expired July 14. Øystein Soug, the company's CEO and primary insider, and his close associate Abakus Invest AS have received their full allocations of subscribed shares and will now hold 109,598 shares, representing about 0.2 percent of the votes and shares in the company following the completion of the offering.